background: recurrent pregnancy loss is (rpl) a heterogeneous condition. while the role of acquired thrombophilia has been accepted as an etiology for rpl, the contribution of specific inherited thrombophilic gene polymorphisms to the disorder has been remained controversial. methods: one hundred women with a history of two or more consecutive abortions and 100 women with at least two live birt...

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manus...

The binding of plasma factor XIII to fibrinogen or fibrin that has been chemically or enzymatically induced to polymerize was studied. Factor XIII binding was assayed using a 3H-putrescine incorporation assay and an 125I-plasma factor XIII binding assay. More than 80% of the native and radiolabeled plasma factor XIII was bound to fibrin I formed by reptilase in EDTA, citrate, or heparin anticoa...

Factor XIII (Fibrin-stabilizing factor) is a tetrameric structural pro-transglutaminase from the transglutaminase family. Factor XIII activity is associated with the structure of fibrin clot. Factor XIII turns into XIII-A, which is an active transglutaminase, in the result phase of coagulation cascade together with Ca and thrombin activation. The main aim of Factor XIIIA is to connect ε(δ-gluta...

In spontaneous fibrinolysis of an alpha 2-plasmin inhibitor-deficient plasma clot or tissue-type plasminogen activator-induced fibrinolysis in a purified system without alpha 2-plasmin inhibitor, the lysis was faster when factor XIII-mediated crosslinking of fibrin to fibrin did not occur. During the initial period, the binding of plasminogen to fibrin steadily increased with incubation time. T...

Thrombin cleavage of blood coagulation Factor XIII (a2b2) and fibrinogen was studied during in vitro clotting to determine the physiologic sequence of these events. First, the time course of fibrin formation and cleavage of Factor XIII was measured in platelet-rich plasma. Cleavage of fibrinogen was measured by using a radioimmunoassay for fibrinopeptide A. Conversion of trace amounts of radioi...